Lexeo Therapeutics partners with Apertura Gene Therapy for TfR1 CapX access in Friedreich ataxia program - LXEO News | RalliesLexeo Therapeutics partners with Apertura Gene Therapy for TfR1 CapX access in Friedreich ataxia program
L
LXEO• Partnership gives Lexeo access to TfR1 CapX
- Lexeo Therapeutics entered an agreement with Apertura Gene Therapy for access to TfR1 CapX for a Friedreich ataxia gene-therapy program.
- TfR1 CapX is an intravenously delivered AAV capsid designed to target hTfR1 and cross the blood-brain barrier.
- Lexeo plans to evaluate a less invasive CNS delivery route following initial systemic administration of LX2006.
SLV
•
